SAN FRANCISCO: Heather Cheng was very much in favour of using enzalutamide after abiraterone since her data show a 30 per cent response rate even in a third of patients who had not responded at all to abi, and higher proportions in both abi-responders and abi-naïve patients. She believed this indicates non-cross-resistance between these two agents.
Heather H Cheng MD PhD, Fred Hutchinson Cancer Research Center
“The effect of prior abiraterone (Abi) use on the activity of enzalutamide (Enza) in men with mCRPC.”
Ambstract 18
ASCO 2014 Genitourinary Cancers Symposium
